Skip to main content

Table 1 Blood collection plan

From: A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

Sample
(Blood)
Volume (mL) Cycle Day Sample No. Scheduled time relative to BEZ235 dosing post-dose (hours)
  3 1 1 1 Pre-dose
     2 1 h post-dose
  3 1 1 3 2 h post-dose
  3 1 1 4 3 h post-dose
     5 5 h post dose
  3 1 1 6 8–12 h post-dose
(optional) 3 1 2 7 24 h post-dose (trough)
  3 1 15 8 Pre-dose
  3 1 15 9 1 h post-dose
  3 1 15 10 3 h post-dose
  3 1 15 11 5 h post-dose
(optional) 3 1 15 12 8–12 h post-dose
  1. Blood sample collection plan in the BEZ 235 phase I trial for PK and PD analysis is shown